Eli Lilly and Co
Change company Symbol lookup
Select an option...
LLY Eli Lilly and Co
GFF Griffon Corp
PSXP Phillips 66 Partners LP
EQ Equillium Inc
TSLA Tesla Inc
OPK OPKO Health Inc
PNW Pinnacle West Capital Corp
ROLL RBC Bearings Inc
GLAD Gladstone Capital Corp
PAC Grupo Aeroportuario del Pacifico SAB de CV
Go

Health Care : Pharmaceuticals | Large Cap Blend
Company profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2018, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.

Closing Price
$130.46
Day's Change
-2.09 (-1.58%)
Bid
--
Ask
--
B/A Size
--
Day's High
133.11
Day's Low
129.21
Volume
(Average)
Volume:
4,336,046

10-day average volume:
4,039,002
4,336,046

LLY's position in the Pharmaceuticals industry

Industry PeersLLYBMYZTSRETAITCI

Summary

Company ProfileEli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health...
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products...
Go to BMY summary
Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has...
Go to ZTS summary
Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of...
Go to RETA summary
Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in...
Go to ITCI summary
52-Week Change

VS. INDUSTRY
14.49%
1.88%
23.94%
-43.37%
166.70%
Market Cap

VS. INDUSTRY
$124.8B
$131.7B
$75.3B
$3.9B
$1.9B
Beta

VS. INDUSTRY
0.3
0.6
0.7
1.6
1.6
Dividend Yield

VS. INDUSTRY
2.27%
3.08%
0.50%
--
--
P/E (TTM, GAAP)

VS. INDUSTRY
21.36x
--
46.90x
--
--
Data as of

Fundamentals

Total Revenue (TTM)

VS. INDUSTRY
$23.2B
$34.9B
$6.3B
$15.3M
$3.1M
Profit Margin

VS. INDUSTRY
24.01%
-1.55%
25.49%
-2,237.15%
-6,115.52%
Earnings Growth
(5 year, GAAP)

VS. INDUSTRY
17.37%
10.85%
21.80%
--
--
Revenue Growth (TTM)

VS. INDUSTRY
6.28%
46.13%
4.86%
-47.52%
--
Data as of
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.